Kaiser Permanente Northern California (San Francisco) Hematology and Medical Oncology

Topics

• Ovarian cancer diagnosis and treatment 95
• CAR-T cell therapy research 20
• Monoclonal and Polyclonal Antibodies Research 20
• Prostate Cancer Treatment and Research 18
• Breast Cancer Treatment Studies 17
• Lymphoma Diagnosis and Treatment 15
• Cutaneous lymphoproliferative disorders research 14
• Hematopoietic Stem Cell Transplantation 14
• Cancer survivorship and care 13
• PARP inhibition in cancer therapy 13
• Endometrial and Cervical Cancer Treatments 9
• Multiple Myeloma Research and Treatments 9

Most cited

1. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

   Nature medicine · 2021 · 534 citations · Wen-Kai Weng

2. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.

   The Lancet. Oncology · 2025 · 84 citations · Wen-Kai Weng

3. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 336 citations · Michael Bookman

4. Donor regulatory T-cell therapy to prevent graft-versus-host disease.

   Blood · 2025 · 40 citations · Wen-Kai Weng

5. Modular design of synthetic receptors for programmed gene regulation in cell therapies.

   Cell · 2022 · 161 citations · Raymond Liu

6. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

   Blood advances · 2021 · 172 citations ·